Nanjing XinBell Pharmaceutical Technology Co., Ltd. is a customer-oriented company, who is specialized in pharmaceutical products developing and marketing. Our manufacturing sites comply to GMP guideline. Documentation support are available for regulated markets. We mainly supply the following intermediates of API: Alvimopan, Asenapine maleate, Azelnidipine, Azilsartan kamedoxomil, Bazedoxifene, Bendamustine hydrochloride, Brivaracetam, Ezetimibe, Finafloxacin, Ligustrazine, Lumacaftor, Memantine hydrochloride, Niraparib, Tazobactam sodium, Tofacitinib, Topiroxostat, Venetoclax, Vonoprazan Fumarate.
more >
Year of Establishment:
-
Total Assets(USD):
choose not to disclose
Total Number of Staff:
less than 10 person
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
R&D capacity:
Annual Turnover(USD):
choose not to disclose
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Other Competitive Advantages:
Patents and Copyrights: